Diametric Capital, LP Argenx Se Transaction History

Diametric Capital, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$108.83 - $165.23 $317,021 - $481,314	-2,913 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$106.59 - $164.21 $310,496 - $478,343	2,913 New	2,913 $468,000
Q2 2019 Aug 14, 2019	SELL	$115.0 - $141.58 $310,040 - $381,699	-2,696 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$98.85 - $134.59 $266,499 - $362,854	2,696 New	2,696 $337,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Diametric Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Diametric Capital, LP with notifications on news.